Gastrointestinal Cancer News

Studies funded by pharmaceutical companies appeared significantly more likely to find oncology drugs cost-effective than studies without such funding, according to results of a cross-sectional study published in JAMA Network Open.

Molecules in saliva may be highly sensitive and specific noninvasive biomarkers of hepatocellular carcinoma, according to a study published in PeerJ.

Trial-ineligible patients with advanced cancer appeared nearly twice as likely as trial-eligible patients to receive immunotherapy, despite no evidence of a survival benefit compared with chemotherapy for this population.

President Joe Biden has unfinished business with cancer.

Residents of rural areas demonstrated higher levels of cancer fatalism and cancer information overload than urban residents, according to a study in Cancer Epidemiology, Biomarkers & Prevention.

The FDA granted orphan drug designation to CTB001, an investigational chimeric antigen receptor T-cell therapy for treatment of certain gastric cancers.

Weight loss during the first 3 months of systemic therapy for metastatic colorectal cancer coincided with significantly shorter OS compared with stable or increasing weight, according to study results.

The combination of cabozantinib and durvalumab appeared safe and demonstrated efficacy among a small cohort of patients with advanced mismatch repair-proficient/microsatellite-stable colorectal cancer, according to study results.

Robotic-assisted surgery significantly improved outcomes compared with laparoscopic surgery among patients with middle and low rectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

First-line pembrolizumab remained effective, safe and noninferior to chemotherapy among certain patients with PD-L1-positive advanced gastric, gastroesophageal junction cancer, according to follow-up results of the KEYNOTE-062 study.